CEMI Chembio Diagnostics

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Company profile

Richard L. Eberly
Fiscal year end
Former names
Chembio Diagnostics Inc., TRADING SOLUTIONS COM INC
Chembio Diagnostic Systems Inc. • Chembio Diagnostics Brazil Holdings LLC • Chembio Diagnostics Brazil Ltda. • Chembio Diagnostics Malaysia Sdn. Bhd. • Chembio Diagnostics Germany Holdings GmbH • Chembio Diagnostics GmbH ...
IRS number

CEMI stock data



9 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.56M 5.56M 5.56M 5.56M 5.56M 5.56M
Cash burn (monthly) 2.93M 2.57M 3.02M 2.21M 2.88M 2.29M
Cash used (since last report) 10.59M 9.3M 10.92M 8M 10.42M 8.27M
Cash remaining -5.02M -3.73M -5.36M -2.43M -4.86M -2.71M
Runway (months of cash) -1.7 -1.5 -1.8 -1.1 -1.7 -1.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Mar 21 Richard Eberly Common Stock Gift Acquire G Yes No 0 51,413 0 51,413
16 Mar 21 Richard Eberly Common Stock Gift Dispose G No No 0 51,413 0 0
16 Mar 21 Richard Eberly Common Stock Payment of exercise Dispose F No No 4.35 26,450 115.06K 51,413
16 Mar 21 Richard Eberly Common Stock Option exercise Acquire M No No 0 77,863 0 77,863
16 Mar 21 Richard Eberly RSU Common Stock Option exercise Dispose M No No 0 77,863 0 155,726
15 Mar 21 Neil A Goldman Incentive Stock Options Common Stock Grant Acquire A No No 4.65 107,143 498.21K 107,143
15 Mar 21 Neil A Goldman RSU Common Stock Grant Acquire A No No 0 38,710 0 38,710
15 Mar 21 Richard Eberly Incentive Stock Options Common Stock Grant Acquire A No No 4.65 321,429 1.49M 321,429
15 Mar 21 Richard Eberly RSU Common Stock Grant Acquire A No No 0 116,129 0 116,129
15 Mar 21 Esfandiari Javan Incentive Stock Options Common Stock Grant Acquire A No No 4.65 107,143 498.21K 107,143

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • We have refocused our business strategy to respond to COVID‑19, which is a new and rapidly developing market, making it difficult to evaluate our business and future prospects.
  • We are allocating substantially all of our resources to the development and production of COVID‑19 Test Systems for the foreseeable future, and our long‑term business success could be negatively impacted by our diversion of resources from our legacy business of diagnostic testing for other infectious diseases.
  • The diagnostic testing market, particularly with respect to COVID‑19, is highly competitive, and many of our competitors are larger, better established and have greater technical and marketing capabilities and financial and other resources than we have.
  • Shareholder litigation could negatively impact our business, operating results and financial condition.
  • We expect competition to with respect to testing solutions for COVID‑19 to continue to increase and our success will depend on widespread market acceptance of our products.
  • The COVID‑19 pandemic could affect our suppliers and employees, and cause disruptions in current and future plans for operations and expansion.
  • We operate in a fragmented, segmented, and rapidly changing industry, which is highly competitive with respect to numerous factors, and our success depends on our ability compete effectively with larger companies, develop new or enhance existing products, as well as acceptance of DPP over more traditional diagnostic platform technologies.
  • Our competitors may develop and commercialize more effective or successful products, and our research, development and commercialization efforts may not succeed.
  • Our products may not be able to compete with new diagnostic products or existing products developed by well‑established competitors, which would negatively affect our business.
  • Our future revenues and operating results may be negatively affected by ongoing consolidation in the healthcare industry.
  • Our continued growth depends on retaining our current key employees and attracting additional qualified personnel, and we may not be able to do so.
  • We may not generate the expected benefits of our acquisitions of opTricon GmbH or Orangelife Comercio e Industria Ltda. and the ongoing integration of the acquisitions could disrupt our ongoing business, distract our management and increase our expenses.
  • Third‑party reimbursement policies and potential cost constraints could negatively affect our business.
  • To the extent that we are unable to collect our outstanding accounts receivable, our operating results could be materially harmed.
  • We believe our success depends in part on the continued funding of, and our ability to participate in, large testing programs in the U.S. And worldwide, the funding of which may be reduced or discontinued or otherwise be unavailable to us.
  • Developing testing guidelines could negatively affect sales of our products.
  • Some of our programs are partially supported by government grant awards, which may not be available to us in the future.
  • Our ability to efficiently operate our business is reliant on information technology, and any material failure, inadequacy, interruption or security breach of that technology could harm our business.
  • If there is an increase in demand for our products, it could require us to expend considerable resources or harm our customer relationships if we are unable to meet that demand.
  • Our management and larger stockholders exercise significant control over us.
  • For our business to succeed in the future, our current and future products must receive market acceptance.
  • We may not have sufficient resources to effectively introduce and market our products, which could materially harm our operating results.
  • New developments in health treatments and non‑diagnostic products may reduce or eliminate the demand for our products.
  • Our future success will depend on our ability to increase manufacturing production capacity through the implementation of additional customized manufacturing automation equipment.
  • Sales cycles for our products can be lengthy, which can cause variability and unpredictability in our business.
  • We may face product liability claims for injuries.
  • Our customers may not adopt rapid point‑of‑care diagnostic testing.
  • Customer concentration creates risks for our business.
  • If our products do not perform properly, it may affect our revenues, stock price and reputation.
  • We have incurred losses in recent years and we are uncertain about our future profitability.
  • Our financial results may fluctuate.
  • The failure to comply with the terms of our Credit Agreement and Guaranty could result in a default under its terms and, if uncured, could result in action against our pledged assets and dilution of our stockholders.
  • The LIBOR calculation method may change, and LIBOR is expected to be phased out after 2021, which may adversely affect our interest expenses under the Credit Agreement and Guaranty.
  • Our operating results may be negatively affected by changes in foreign currency exchange rates.
  • We operate in countries where there is or may be widespread corruption.
  • Changes in interpretation or application of U.S. Generally Accepted Accounting Principles may adversely affect our operating results.
  • We base our estimates or judgments relating to critical accounting policies on assumptions that can change or prove to be incorrect.
  • Our success depends on our ability to protect our proprietary technology. We rely on trade secret laws and agreements with our key employees and other third parties to protect our proprietary rights, and we cannot be sure that these laws or agreements will adequately protect our rights.
  • Any future intellectual property disputes could require significant resource and limit or eliminate our ability to sell products or use certain technologies.
  • Our use of third‑party suppliers, some of which may constitute our sole supply source, for certain important product components and materials presents risks that could have negative consequences for our business.
  • We may work with strategic collaborators to assist in developing and commercializing our products, which could limit rights we receive from the collaborations and exposes us to other risks outside our control.
  • Our ability to grow our business will be limited if we fail to maintain existing distribution channels or develop new distribution channels.
  • Our U.S. Government contracts require compliance with numerous laws and increases our risk and liability.
  • Our U.S. government contracts are subject to future funding and the government’s choice to exercise options, and may be terminated at the government’s convenience.
  • We are subject to governmental export controls that could impair our ability to compete in international markets.
  • Because we may not be able to obtain or maintain the necessary regulatory approvals for some of our products, we may not generate revenues in the amounts we expect, or in the amounts necessary to continue our business. Our existing products as well as our manufacturing facility must meet quality standards and are subject to inspection by a number of domestic regulatory and other governmental and non‑governmental agencies.
  • If we do not comply with FDA or other regulatory requirements, we may be required to suspend production or sale of our products or institute a recall, which could result in higher costs and a loss of revenues.
  • Our inability to respond to changes in regulatory requirements could adversely affect our business.
  • Demand for our products may be affected by FDA regulation of laboratory‑developed tests and genetic testing.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved, authorized, or commercialized in a timely manner or at all, which could negatively impact our business.
  • In addition to FDA requirements, we are subject to several government regulations, compliance with which could increase our costs and affect our operations.
  • Ongoing changes in healthcare regulation could negatively affect our revenues, business and financial condition.
  • We may incur additional costs if we do not comply with privacy, security and breach notification regulations.
  • Failure to comply with recent European data protection requirements could increase our costs.
  • If we are not able to manufacture products in accordance with applicable requirements, it could adversely affect our business.
  • Healthcare fraud and abuse laws could adversely affect our business and results of operations.
  • Our compliance with regulations governing public companies is complex and expensive.
  • If we expand our international presence, it may increase our risks and expose our business to regulatory, cultural or other challenges.
  • Our Common Stock has limited liquidity, and investors may not be able to sell as much stock as they want at prevailing market prices or at all.
  • The price of our Common Stock could continue to be volatile.
  • Our Common Stock may become the target of a “short squeeze.”
  • Any future issuances of shares of our Common Stock by us could harm the price of our Common Stock and our ability to raise funds in new equity offerings.
  • Sales of our Common Stock by existing stockholders, executive officers or directors could depress the market price of our Common Stock.
  • We do not intend to pay cash dividends on our Common Stock.
  • We may not generate the expected benefits of future acquisitions or investments, and they could disrupt our ongoing business, distract our management, increase our expenses and negatively affect our business.
  • Developments related to the U.K.’s referendum on membership in the E.U. could adversely affect us.
  • Legislative and other regulatory changes could have an effect on our business.
  • Our business may be negatively affected by terrorist attacks or natural disasters.
Content analysis
H.S. junior Avg
New words: adjourn, assigned, ATM, bankruptcy, Centre, Chair, Chapter, compensatory, configure, cooperating, Craig, discourage, Dispute, earliest, East, endeavor, Ethiopia, forty, freestanding, Hallum, harder, history, inquiry, insolvency, involuntary, jury, maker, maximize, maximum, meruit, Middle, mutual, opinion, ordinary, OTIP, Partnership, placement, Pool, power, preceding, predominantly, prejudgment, qualification, quantum, quorum, receivership, recommendation, renegotiate, rent, repeatedly, retention, salable, shelf, sixty, solid, staffing, stemming, stricter, subpoena, substance, Tier, tour, unanticipated, underwent, unjustly, unlawful, unspecified, urged, viable, Vice, voluntary, warehouse, wholly, worksite, wrongfully, XI, XII, XIII, XIV, XV
Removed: acceptance, accuracy, accurate, agency, analytical, analyzer, announced, approvable, attention, attracting, avoid, billion, biological, broader, calculated, care, challenge, collaborate, commerce, commercialized, community, compete, competition, complex, complicated, component, comprehensive, concentration, concurrently, conduct, Cosmetic, created, criteria, decentralized, decreased, defend, demonstrate, detect, detecting, determination, determining, device, diagnose, disruption, distinct, distributor, drop, ease, elimination, emerging, encouraged, enforcement, engineering, enhance, enroll, entrance, error, European, eventually, evolve, exercisable, expanding, experienced, exposed, exposure, facilitate, fail, framework, gain, healthcare, identification, importance, impose, impossible, impractical, improved, inception, infrastructure, inherent, injury, institute, intense, intention, internationally, introduce, introduced, introduction, involving, larger, led, legislation, license, marketed, medicine, molecular, monetary, multiplex, nature, necessitate, office, optical, originally, patent, patient, people, perform, PMA, policy, portability, portable, potentially, premarket, preparation, presence, prevalent, processing, profitable, promulgated, pursuit, qualified, rapidly, reaction, recommence, recurring, refocused, represent, resigned, response, resume, revised, royalty, separately, serology, servicing, shift, ship, shipping, short, size, small, specific, storage, strong, structure, study, submission, substitution, surveillance, targeted, termination, trailing, transfer, translated, translation, treat, treatment, type, typically, ultimate, ultimately, unclear, uncollectible, unexpected, UNICEF, Union, unique, unpredictable, vaccine, variability, variable, variety, version, visual, vitro, wide, workforce, worldwide, yield, ZCD, Zika